CSPC PHARMA (01093) has released a positive profit alert, announcing that the group expects its consolidated net profit attributable to shareholders for the six months ending June 30, 2026 (the reporting period) to be between approximately RMB 5.90 billion and RMB 6.20 billion.

This represents a significant increase compared to the RMB 2.55 billion in consolidated net profit attributable to shareholders recorded for the six months ending June 30, 2025.

The growth is primarily driven by a combination of factors. A key contributor is a substantial increase in licensing fee income compared to the same period last year. An upfront payment of USD 840 million (approximately RMB 5.74 billion) from this source is expected to be recognized as licensing fee revenue in the second quarter of 2026, providing a major revenue contribution for the group during the reporting period.

Excluding the impact of this licensing fee income, the group's finished drugs business has shown steady growth. The sales revenue from this segment during the reporting period increased by approximately 10% compared to the same period last year, continuing to provide solid support for the group's overall profitability.